Evaluating biomarkers in metastatic castration resistant prostate cancer (mCRPC) patients (Pts) treated with enzalutamide (Enza): PSA, circulating tumor cell (CTC) counts, AR-V7 status, PET imaging vs. CT & Tc99 scans-MedSci.cn

Evaluating biomarkers in metastatic castration resistant prostate cancer (mCRPC) patients (Pts) treated with enzalutamide (Enza): PSA, circulating tumor cell (CTC) counts, AR-V7 status, PET imaging vs. CT & Tc99 scans

Gandhy, S; Gonzales, EM; Karzai, F; Marte, J; Bilusic, M; McMahon, S; Strauss, J; Steinberg, S; Gill, A; Tubbs, A; Schonhoft, J; Choyke, P; Turkbey, B; Lindenberg, L; Figg, WD; Arlen, P; Dahut, W; Gulley, JL; Madan, RA

ANNALS OF ONCOLOGY, 2020; 31 (): S527

科室
- - 订阅+
  - 更多科室
工具
服务